Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
45,456actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-06 | actual | When the study began enrolling |
| Primary completion | 2025-03-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-28 | actual | The whole study's end, after follow-up |
| First posted | 2025-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
- Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
- Other: No treatment given
- Other: No treatment given
Primary outcomes
what the primary-completion date above is the date OFRevised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event)
measured Index date, earliest of revised MACE-5 and end of follow-up, up to 30 months
Revised 3-Point Major Adverse Cardiovascular Events (MACE-3) (time-to-event)
measured Index date, earliest of revised MACE-3 and end of follow-up, up to 30 months
Publications
- PMID 40926360 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed